1-3 of 3
Marina V. Kosinova
Close
Sort by
Journal Articles

Prophylactic Treatment of Severe Haemophilia Á Patients with Inhibitors to FVIII with Peglip-FVIII

Margarita Timofeeva, Nadezhda I. Zozulya, Tatiana Pospelova, Marina V Kosinova, Igor Kurtov, Edward Tuddenham, Gavin Ling
Journal: Blood
Blood (2021) 138 (Supplement 1): 1040.
https://doi.org/10.1182/blood-2021-149533
Published: 2021
Journal Articles

Phase 2/3 Trial of Subcutaneously Administered Marzeptacog Alfa (activated) an Engineered FVIIa in Hemophilia with Inhibitors - Pharmacokinetics, Pharmacodynamics, Safety and Efficacy

Howard Levy, PhD MBBChir, Levani Makhaldiani, Genadi Iosava, MD, Johnny Mahlangu, Marina V Kosinova, MD, Heghine Khacchatryan, MD, Frank Del Greco, MBA, Frank V. McL. Booth, MA MSc BM BCh
Journal: Blood
Blood (2018) 132 (Supplement 1): 1198.
https://doi.org/10.1182/blood-2018-99-112567
Published: 2018
Journal Articles

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Clinical Trials & Observations
Johnny Mahlangu, Kazimierz Kuliczkowski, Faraizah Abdul Karim, Oleksandra Stasyshyn, Marina V. Kosinova, Lynda Mae Lepatan, Aleksander Skotnicki, Lisa N. Boggio, Robert Klamroth, Johannes Oldenburg, Andrzej Hellmann, Elena Santagostino, Ross I. Baker, Kathelijn Fischer, Joan C. Gill, Stephanie P’Ng, Pratima Chowdary, Miguel A. Escobar, Claudia Djambas Khayat, Luminita Rusen, Debra Bensen-Kennedy, Nicole Blackman, Tharin Limsakun, Alex Veldman, Katie St. Ledger, Ingrid Pabinger, for the AFFINITY Investigators
Journal: Blood
Blood (2016) 128 (5): 630–637.
https://doi.org/10.1182/blood-2016-01-687434
Published: 2016
Includes: Supplemental data